Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation

被引：135

作者：

Haque, Shadabul ^{[1
,2
]}

Md, Shadab ^{[1
]}

Fazil, Mohammad ^{[1
]}

Kumar, Manish ^{[3
]}

Sahni, Jasjeet Kaur ^{[1
]}

Ali, Javed ^{[1
]}

Baboota, Sanjula ^{[1
]}

机构：

[1] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India

[2] Ranbaxy Res Labs, Gurgaon, India

[3] Jawaharlal Nehru Univ, Adv Instrumentat Res Facil, New Delhi 110067, India

来源：

CARBOHYDRATE POLYMERS | 2012年 / 89卷 / 01期

关键词：

Biodistribution; Brain targeting; Chitosan; Confocal microscopy; Intranasal route; Venlafaxine; DRUG-DELIVERY SYSTEM; IN-VITRO; INTRANASAL; NANOPARTICLES; FORMULATION; INSULIN;

D O I：

10.1016/j.carbpol.2012.02.051

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

The purpose of the present investigation was to prepare venlafaxine (VLF) loaded chitosan nanoparticles (NPs) to enhance the uptake of VLF to brain via intranasal (in.) delivery. VLF loaded chitosan NPs were prepared and characterized for particle size, size distribution, zeta potential, encapsulation efficiency and in vitro drug release. In order to investigate the localization of chitosan NPs in brain and other organs qualitatively confocal laser scanning microscopy technique was carried out using rhodamine-123 (ROD-123) as marker. The levels of VLF in plasma and brain tissues were also determined, the brain/blood ratios of VLF for VLF (i.v.), VLF (i.n.), VLF chitosan NPs (in.) were 0.0293, 0.0700 and 0.1612, respectively, at 0.5 h, indicative of better brain uptake of VLF chitosan NPs. The higher drug transport efficiency (508.59) and direct transport percentage (80.34) of VLF chitosan NPs as compared to other formulations suggest its better efficacy in treatment of depression. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：72 / 79

页数：8

共 34 条

[1] Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses [J].

Al-Ghananeem, Abeer M. ;

Saeed, Hayder ;

Florence, Rebecca ;

Yokel, Robert A. ;

Malkawi, Ahmad H. .

JOURNAL OF DRUG TARGETING, 2010, 18 (05) :381-388

[2] Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration [J].

Ali, Javed ;

Ali, Mushir ;

Baboota, Sanjula ;

Sahni, Jasjeet Kaur ;

Ramassamy, Charles ;

Dao, Le ;

Bhavna .

CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (14) :1644-1653

[3] EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].

ARTURSSON, P ;

LINDMARK, T ;

DAVIS, SS ;

ILLUM, L .

PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361

[4] A study of rivastigmine liposomes for delivery into the brain through intranasal route [J].

Arumugam, Karthik ;

Subramanian, Ganesa Sundararajan ;

Mallayasamy, Surulivel Rajan ;

Averineni, Ranjith Kumar ;

Reddy, Meka Sreenivasa ;

Udupa, Nayanabhirama .

ACTA PHARMACEUTICA, 2008, 58 (03) :287-297

[5] Chitosan and chitosan ethylene oxide propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines [J].

Calvo, P ;

RemunanLopez, C ;

VilaJato, JL ;

Alonso, MJ .

PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1431-1436

[6] Monolithic gelation of chitosan solutions via enzymatic hydrolysis of urea [J].

Chenite, A. ;

Gori, S. ;

Shive, M. ;

Desrosiers, E. ;

Buschmann, M. D. .

CARBOHYDRATE POLYMERS, 2006, 64 (03) :419-424

[7] Assessing antidepressant activity in rodents: recent developments and future needs [J].

Cryan, JF ;

Markou, A ;

Lucki, I .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (05) :238-245

[8] Biomedical applications of nanotechnology - Implications for drug targeting and gene therapy [J].

Davis, SS .

TRENDS IN BIOTECHNOLOGY, 1997, 15 (06) :217-224

[9] BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123 [J].

de Lange, ECM ;

de Bock, G ;

Schinkel, AH ;

de Boer, AG ;

Breimer, DD .

PHARMACEUTICAL RESEARCH, 1998, 15 (11) :1657-1665

[10]

Dhanda DS., 2005, Drug Delivery Technology, V5, P64

← 1 2 3 4 →